Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alkeremes

- PMLiVE

Novartis forms digital health investment company with Qualcomm

Expands work with Tricorder prize firm to develop 'beyond-the-pill' initiatives

Novartis building

Novartis files COPD combo in US

QVA149 combines long-acting beta agonist with long-acting muscarinic antagonist

- PMLiVE

Novartis completes sale of animal health unit to Lilly

$5.4bn deal is finalised

- PMLiVE

Novartis signs stem cell research pact with Intellia

Will work with the biotech start-up on creating new treatments

Novartis day

FDA close to first biosimilar approval

US regulator’s advisory board recommends Novartis’ version of Amgen’s Neupogen

- PMLiVE

Japan first to approve Novartis psoriasis drug Cosentyx

Becomes first company to gain approval for an interleukin-17 inhibitor

- PMLiVE

Novartis’ acromegaly therapy cleared by FDA

Signifor LAR shows superior efficiency to older treatments

- PMLiVE

Novartis’ Afinitor fails frontline breast cancer trial

Drug already approved to treat HER2-negative breast cancer

- PMLiVE

Novartis’ Cosentyx beats Stelara in psoriasis study

Cosentyx achieved clearance in 70% of patients

- PMLiVE

ABPI names first project director for manufacturing

James Christie joins from Oxford BioMedica

- PMLiVE

Ranbaxy hit with EU import ban on antibiotic

Indian generics firm’s plant ruled in breach of manufacturing rules

- PMLiVE

US R&D hit in GSK’s latest cost-cutting round

CRO Parexel rumoured to contract “up to 450” GSK employees

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links